Skip to content

Prospective Assessments Following Immediate Lymphatic Reconstruction

Prospective Assessments Following Immediate Lymphatic Reconstruction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07227467
Enrollment
100
Registered
2025-11-12
Start date
2025-12-01
Completion date
2030-12-31
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphatic Reconstruction

Brief summary

Immediate lymphatic reconstruction (ILR) is a novel surgical approach performed at the time of initial lymph node dissection with the goal of preventing lymphedema.(Chang et al. 2020) It involves the identification of lymphatic channels that are transected after lymph node dissection and microsurgical anastomosis of one or more lymphatic channel with a local recipient vein to re-direct upper extremity lymphatic drainage. Although ILR carries significant promise in prevention of lymphedema, there is a lack of high-level evidence supporting its efficacy because it is a novel surgical technique that is only offered at a few centers and not routinely covered by insurance carriers yet. The University of Chicago Comprehensive Cancer Center (UCCCC) is one of the busiest microsurgery centers performing this procedure, and, as a Lymphedema Center of Excellence, is in a unique position to investigate the efficacy of ILR in preventing lymphedema. In addition, the University has access to a world class microbiome research facility and colleagues. To our knowledge, there is no information on the skin microbiome of the axilla in patients undergoing treatment for breast cancer or those at risk for developing lymphedema. Further exploratory studies such as this in a diverse patient population may lead to practice changing research in our approach to lymphedema management and prevention.

Interventions

OTHERpatients who are candidates for immediate lymphatic reconstruction

potential candidates for ILR based on possible nodal involvement assessed preoperatively.

Sponsors

University of Chicago
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

potential candidates for ILR based on possible nodal involvement assessed preoperatively.

Exclusion criteria

* Individuals who are not eligible for ILR based on possible nodal involvement assessed preoperatively.

Design outcomes

Primary

MeasureTime frameDescription
the efficacy of immediate lymphatic reconstruction (ILR) based on bioimpedance spectroscopy measurements of affected and unaffected limbs of women before and after surgery.post operative study period at 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 48 months and 60 months.Bioimpedance spectroscopy is a non-invasive technology that measures total body water, and both extracellular and intracellular fluid volumes.
The efficacy of immediate lymphatic reconstruction (ILR) based on limb circumference of each armpost operative study period at 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 48 months and 60 months.
the efficacy of immediate lymphatic reconstruction (ILR) based on volumepost operative study period at 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 48 months and 60 months.

Secondary

MeasureTime frameDescription
the impact of ILR on validated patient reported outcome tool using the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES)post operative study period at 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 48 months and 60 months.This is a 10 questionnaire that scales from unable to do it (1) to not difficult (3).
the impact of ILR on validated patient reported outcome tool using the lymphedema life impact scale (LLIS)post operative study period at 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 48 months and 60 months.This is an 18 questionnaire that has a scale from 0 (no pain) to 4 (severe pain)
the impact of ILR on validated patient reported outcome tool using The Disabilities of the Arm, Shoulder and Hand (DASH) questionnairepost operative study period at 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 48 months and 60 months.This is a 30 questionnaire that has a scale from 1 (No difficulty) to 5 (unable)

Other

MeasureTime frameDescription
Comparison of the Axillary Microbiome in ILR-Treated and Untreated Limbspost operative study period at 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 48 months and 60 months.Characterize the axillary microbiome in limbs that have been treated with ILR compared to those that were unaffected before and after surgery.

Countries

United States

Contacts

Primary ContactSummer Hanson, MD, PhD, FACS
sehanson@bsd.uchicago.edu(773) 702-6302

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026